ArticleDiscover oncology2025
Implementation of whole genome sequencing in cancer management: modelling and sensitivity analysis using system dynamics.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Precision oncology using biomarkers and genomic testing facilitates individualised diagnosis and consequently treatment for cancer patients. Standard of Care is conducted through assays of biomarkers for treatment selection. However, Whole Genome Sequencing (WGS) provides excessively more information about actionable mutations and complex interventions. Despite its potentials in cancer management, WGS is restricted by its high cost and limited capacity. Implementing WGS is complex because it influences several elements of the care delivery and deals with the dynamic changes in supply, demand, technology, and cost. In this study, we use a System Dynamics (SD) model to evaluate WGS implementation. We also use the developed SD model to conduct sensitivity analysis to derive insights for decision-making on genomic testing scenarios. Various scenarios have been compared by the number of diagnosed patients and total cost. These scenarios have been created through alterations in WGS referral system, capacity, price, and willingness rate as well as testing time across different hospitals. The results showed that referring more patients for WGS will increase the number of diagnosed patients (by 30%), however it will impose more cost on the system (by 20%) due to higher cost of WGS. Therefore, investment strategies toward reducing cost of WGS as well as reimbursement policies can be beneficial to make WGS more economic and accessible. This study shows how the developed SD model can contribute to providing insights for policy makers in finding the optimal way for implementing WGS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.